A groundbreaking study has revealed the potential of lacosamide as a treatment for neonatal seizures, offering a glimmer of hope for families facing this challenging condition. The phase 2 clinical trial, presented at the 2025 American Epilepsy Society Annual Meeting, showcased lacosamide's effectiveness and safety, providing a much-needed ray of light in the darkness. But here's where it gets controversial...
The study, led by Dr. Wendy Waldman Zadeh, a neurologist at Broadlawns Medical Center, Iowa, enrolled 26 patients, randomizing them to receive either lacosamide or an active comparator. The results were remarkable: a significant reduction in seizure burden and excellent tolerability. Despite the increased exposure of lacosamide in neonates, serum concentrations remained comparable to adult levels, a finding that challenges conventional wisdom.
And this is the part most people miss: the study also explored the use of lacosamide as a second-line treatment for refractory trigeminal neuralgia. A previous retrospective trial demonstrated its potential as an alternative for patients who don't respond to first-line treatments. With more than half of the cohort continuing on their previous therapies, lacosamide offered pain relief to two-thirds of the patients, with mild adverse events.
So, is lacosamide the new frontier in seizure and neuralgia treatment? The data suggests so, but what do you think? Should we embrace this new treatment option, or are there potential pitfalls we should consider? Share your thoughts in the comments and let's spark a conversation about this exciting development in neurology.
